Legend Biotech (LEGN) | Financial Analysis & Statements
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
627.2M
Gross Profit
392.7M
62.60%
Operating Income
-303.2M
-48.35%
Net Income
-177.0M
-28.22%
EPS (Diluted)
-$0.96
Balance Sheet Metrics
Total Assets
1.7B
Total Liabilities
629.6M
Shareholders Equity
1.0B
Debt to Equity
0.61
Cash Flow Metrics
Operating Cash Flow
-69.8M
Free Cash Flow
-158.1M
Revenue & Profitability Trend
Legend Biotech Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 627.2M | 285.1M | 117.0M | 68.8M | 75.0M |
| Cost of Goods Sold | 234.6M | 144.2M | 65.4M | 0 | 0 |
| Gross Profit | 392.7M | 140.9M | 51.6M | 68.8M | 75.0M |
| Operating Expenses | 695.9M | 580.4M | 507.3M | 461.1M | 301.8M |
| Operating Income | -303.2M | -439.5M | -455.6M | -392.3M | -226.8M |
| Pre-tax Income | -158.1M | -520.1M | -445.7M | -407.2M | -308.3M |
| Income Tax | 18.9M | -1.9M | 625.0K | -3.6M | -41.9M |
| Net Income | -177.0M | -518.3M | -446.3M | -403.6M | -266.4M |
| EPS (Diluted) | -$0.96 | -$2.94 | -$2.80 | -$2.74 | -$2.56 |
Income Statement Trend
Legend Biotech Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 1.3B | 1.5B | 1.1B | 949.8M | 593.9M |
| Non-Current Assets | 386.2M | 350.8M | 231.8M | 169.6M | 128.1M |
| Total Assets | 1.7B | 1.8B | 1.3B | 1.1B | 722.1M |
| Liabilities | |||||
| Current Liabilities | 277.6M | 216.4M | 297.8M | 229.2M | 115.6M |
| Non-Current Liabilities | 352.0M | 380.8M | 288.9M | 124.3M | 8.8M |
| Total Liabilities | 629.6M | 597.2M | 586.7M | 353.5M | 124.3M |
| Equity | |||||
| Total Shareholders Equity | 1.0B | 1.3B | 744.3M | 765.9M | 597.8M |
Balance Sheet Composition
Legend Biotech Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -158.1M | -520.1M | -445.7M | -407.2M | -308.3M |
| Operating Cash Flow | -69.8M | -509.1M | -318.7M | -349.4M | -263.5M |
| Investing Activities | |||||
| Capital Expenditures | -14.1M | -20.1M | -20.9M | -42.2M | -26.3M |
| Investing Cash Flow | -850.5M | 95.4M | -75.7M | -191.8M | -20.1M |
| Financing Activities | |||||
| Dividends Paid | - | - | - | - | - |
| Financing Cash Flow | -4.0M | 579.9M | 375.0M | 622.0M | 617.4M |
| Free Cash Flow | -158.1M | -416.0M | -223.6M | -243.9M | -253.3M |
Cash Flow Trend
Legend Biotech Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-35.73
Forward P/E
-50.52
Price to Book
6.12
Price to Sales
8.55
PEG Ratio
-50.52
Profitability Ratios
Profit Margin
-29.95%
Operating Margin
-25.97%
Return on Equity
-20.00%
Return on Assets
-8.77%
Financial Health
Current Ratio
5.20
Debt to Equity
35.65
Beta
0.13
Per Share Data
EPS (TTM)
-$1.18
Book Value per Share
$5.53
Revenue per Share
$3.97
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| legn | 6.2B | -35.73 | 6.12 | -20.00% | -29.95% | 35.65 |
| Vertex | 114.1B | 32.82 | 6.92 | -5.64% | -8.91% | 10.00 |
| Regeneron | 55.3B | 13.02 | 1.84 | 15.96% | 31.94% | 9.20 |
| Blueprint Medicines | 8.3B | -120.00 | 24.19 | -47.71% | -27.70% | 208.50 |
| Roivant Sciences | 7.8B | 1.95 | 1.71 | -12.54% | 96.86% | 1.93 |
| Bio-Techne | 7.9B | 60.87 | 3.92 | 6.53% | 10.89% | 20.99 |
Financial data is updated regularly. All figures are in the company's reporting currency.